Prevymis (letermovir) - Merck (MSD)
Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors (clinicaltrialsregister.eu) - May 28, 2026 - P1/2 | N=80 | Recruiting | Sponsor: Grupo Espaol de Trasplantes Hematopoyticos y Terapia Celular | Not yet recruiting ➔ Recruiting 
Enrollment open • Cytomegalovirus Infection • Infectious Disease • Transplantation
https://euclinicaltrials.eu/ctis-public/view/2024-516011-24-01
 
May 28, 2026
 
Prev Next